卡维地洛对不稳定型心绞痛患者血清细胞因子和心肌缺血的影响

目的：探讨卡维地洛对不稳定型心绞痛患者血清细胞因子和心肌缺血的影响。方法：选择100例不稳定型心绞痛患者，分为卡维地洛组和常规治疗对照组（各50例），测定治疗前后可溶性细胞间粘附分子-1（sICAM-1）和可溶性P-选择素（P-selectin）水平，并观察两组患者治疗前后心肌缺血指标的变化。结果：卡维地洛组和常规治疗对照组患者治疗6个月后血清sICAM-1和可溶性P-选择素水平较治疗前明显降低（P〈0．01，〈0．05），其中卡维地洛组患者血清sICAM-1和可溶性P-选择素水平降低较对照组更为明显（P均〈0．05）。卡维地洛组和常规治疗对照组患者心绞痛持续时间缩短，ST段下移减轻（P〈0．01，〈0．05），但卡维地洛组疗效更加明显（P〈0．05）；卡维地洛组的临床疗效总有效率94％，优于常规治疗对照组的72％（P〈0．05）。结论：卡维地洛可以降低不稳定型心绞痛患者血清sICAM-1和可溶性P-选择素水平，抑制冠脉粥样病变的炎症反应，改善心肌缺血症状，是治疗不稳定型心绞痛的理想药物。

Effects of carvedilol on the serum cytokine levels and myocardial ischemia of patients with unstable angina pectoris

Objective： To investigate the effects of carvedilol on the serum cytokine levels and myocardial ischemia of patients with unstable angina pectoris （UAP）. Methods： A total of 50 cases of traditional treatment group （control group） and 50 cases of carvedilol group were chosen. The serum levels of soluble intercellular adhesion molecules- 1 （sICAM-1） and soluble P-selectin were measured before and after treatment in two groups and the parameters of myocardial ischemia before and after treatment were observed. Results： The serum levels of sICAM-1 and soluble P -selectin in carvedilol group and control group significantly decreased after 6 months of treatment as compared with before treatment （P〈0.05, all）; compared with the control group, the changes in carvedilol group were more than （P〈0.05 all）. The total effective rate of carvedilol group was more （94%, P〈0.05） compared with the control group （72%）. The duration time of attack of angina pectoris shortened, and ST depression relieved （P〈0.01 all） in carvedilol group and was more than those of control group. （P〈0.05 all）. Conclusion： Carvedilol can lower the serum levels of sICAM-1 and soluble P-selectin in patients with unstable angina pectoris, suppress the inflammation response, and improve the symptom of angina pectoris. Therefore, carvedilol is an ideal medicine for therapy of unstable angina oectoris.